02.22.2023

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

02.21.2023

U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

02.16.2023

Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study

02.16.2023

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

02.10.2023

FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)

02.09.2023

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.31.2023

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE

01.17.2023

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries

01.06.2023

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children

01.03.2023

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.29.2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate

12.28.2022

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents